- Published on
Infectious Disease - Bronchitis
BRONCHITIS
Bronchitis is an inflammation of the lining of the tracheobronchial tree. It is typically categorized as acute or chronic.
Acute bronchitis is defined by a cough, sometimes accompanied by sputum production, lasting less than three weeks.
Chronic bronchitis is clinically defined as a chronic productive cough lasting a minimum of 3 months over a span of 2 consecutive years.
Epidemiology
Occurrence
Chronic bronchitis impacts over 9.5 million Americans annually.
Approximately 10 million individuals pursue medical treatment for acute bronchitis annually.
Acute bronchitis: Present in all age demographics. Affects both males and females equally.
• Chronic bronchitis: Predominantly observed in adults over the age of 50. Males are more adversely impacted than females.
RISK FACTORS
• Acute bronchitis: – Tobacco use – Respiratory irritants, such as exposure to chemicals and air pollution
Upper respiratory tract infections, chronic lung diseases, advanced age, and diminished immunity elevate the risk of acute bronchitis upon exposure to respiratory irritants. • Chronic bronchitis: – Tobacco use – Respiratory irritants, such as exposure to chemicals and air pollution
- Recurrent upper respiratory tract infections, allergies – 50 years of age
Genetics
Heritability exerts a moderate impact on the progression of chronic bronchitis.
GENERAL PREVENTION MEASURES
• Refrain from smoking and exposure to second-hand smoke and irritants. • Avoid interaction with those suffering from upper respiratory tract diseases. Annual influenza vaccination; pneumococcal vaccination every 5 to 10 years for individuals aged 65 or older or those with chronic diseases.
PATHOPHYSIOLOGY
• Irritation of bronchial lining tissue causes hyperemia and edema of the mucous membrane • Excessive mucus production • Hyperreactivity of bronchial smooth muscle resulting in bronchospasm • Increased airflow resistance leading to hypoventilation, subsequently causing hypercarbia and hypoxemia
CAUSE
• Acute bronchitis: - often induced by viral pathogens:
Viruses Influenza A and B Parainfluenza virus Respiratory syncytial virus
Coronavirus and Adenovirus Rhinovirus - Atypical microorganisms are significant contributors in certain instances:
Mycoplasma pneumoniae Chlamydia pneumoniae Bordetella pertussis: Chronic bronchitis
– Tobacco use – Environmental contaminants • Acute aggravation of chronic bronchitis: Haemophilus influenzae
– Moraxella catarrhalis – Pseudomonas aeruginosa and Enterobacteriaceae are more frequent in patients with significant lung function impairment
Streptococcus pneumoniae – Viral infections – Chlamydophila pneumoniae
- Environmental variables (atmospheric contaminants, allergens, thermal fluctuations, irritants such as dust and tobacco smoke)
FREQUENTLY CO-OCCURRING CONDITIONS
• Upper respiratory tract infection • Bronchial asthma • Chronic bronchitis linked with emphysema
chronic obstructive pulmonary disease
DIAGNOSTIC HISTORY
• Acute bronchitis:
– Recent history of a respiratory infection or sinusitis – Exposure to allergens or irritants – Occupational history involving exposure to irritants - Primary or secondary smoking
• Chronic bronchitis: – As previously mentioned – History of productive cough • Acute aggravation of chronic bronchitis: – Elevated dyspnea – Augmented sputum output – Enhanced sputum purulence Symptoms may encompass moderate fever, sore throat, exertional dyspnea, wheezing, chest tightness, chest discomfort, weariness, malaise, and headaches.
PHYSICAL EXAMINATION
• Fever is infrequent • Tachypnea and tachycardia are attributable to infection
• Indicators of upper respiratory tract infection • Harsh breath sounds/wheezing/prolonged expiration • Decline in respiratory function typically arises with acute exacerbations of chronic bronchitis
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory
Preliminary laboratory examinations
• Complete Blood Count (CBC) • Sputum cultures to identify particular pathogenic bacteria • Serum procalcitonin may assist in determining whether individuals require antibiotics (2).
• Pulse oximetry and arterial blood gas analyses
Subsequent Actions & Unique Considerations
Spirometry may be conducted many weeks post-recovery to evaluate lung function and measure airway blockage.
Imaging: Preliminary Strategy
Chest radiograph to exclude pneumonia
Subsequent Actions & Unique Considerations
Subsequent chest radiography is typically unnecessary.
Diagnostic Procedures and Additional Methods
• Assessment of pulmonary function • Bronchoscopy Pathological Findings
• Acute bronchitis:
Mucosal or submucosal edema
- Inflammatory cells in the mucosa and submucosa • Chronic bronchitis:
– Hyperplasia of goblet cells – Inflammatory cells in the mucosa and submucosa Mucus obstruction; smooth muscle hyperplasia.
DIFFERENTIAL DIAGNOSIS
• Asthma • Bronchiolitis • Pneumonia • Pharyngitis
• Bronchiectasis • Chronic sinusitis • Pulmonary embolism with infarction • Congestive heart failure
• Wegener's granulomatosis • Sarcoidosis • Atelectasis • Chemical pneumonitis • Gastroesophageal reflux disease
THERAPEUTIC PHARMACEUTICAL
Initial Line
• Acute bronchitis: Treatment is not indicated unless the following conditions are present (3–5):
– Influenza virus:
Oseltamivir 75 mg orally, twice daily for five days Zanamivir, 2 inhalations (5 mg each inhalation) Twice daily for five days
– Bordetella pertussis:
Azithromycin for 5 days, administered at a dosage of 500 mg on the first day and 250 mg on subsequent days. Two to five Erythromycin 500 mg four times daily for 14 days Clarithromycin 500 mg twice day for 7 days
M. pneumoniae/C. pneumoniae:
No treatment (no persuasive evidence indicating enhanced outcomes from the use of antibacterial medicines)
Azithromycin for 5 days, administered at a dosage of 500 mg on the first day and 250 mg on subsequent days. Doxycycline 100 mg twice day for 5 days
• Acute aggravation of chronic bronchitis
Bacterial infections: – Amoxicillin 250–500 mg orally every 8 hours; – Amoxicillin and clavulanate 500 mg orally every 8 hours for 5–10 days; – Trimethoprim–sulfamethoxazole 160 mg trimethoprim/800 mg sulfamethoxazole orally every 12 hours for 5–10 days.
Doxycycline 100 mg orally twice day on day 1, followed by 100 mg orally once daily for 5 to 10 days.
– Short-term administration of quinolones or macrolides (for 5 days) is not less effective than prolonged treatment (7–10 days) (6)[A].
Levofloxacin 250 mg orally twice daily or 500 mg orally once daily for five days.
Ciprofloxacin 250–500 mg orally, twice day for five days. - Clarithromycin 250–500 mg orally twice daily for 5 days
- Azithromycin for 5 days: 500 mg on day 1 and 250 mg on days 2 to 5. Line
• Acute bronchitis: – B. pertussis: Trimethoprim-sulfamethoxazole 1600 mg daily for 14 days or 800 mg twice day for 14 days
SUPPLEMENTARY THERAPY
General Measures • Avoidance of environmental irritants • Administration of bronchodilators for dyspnea management • Implementation of low-flow oxygen therapy during exacerbations • Utilization of systemic corticosteroids during exacerbations • Employment of antitussive agents (codeine and dextromethorphan) for short-term symptomatic relief of cough in patients with acute and chronic bronchitis Referral Considerations
Recurrent and intense exacerbations
Supplementary Treatments
• Pulmonary rehabilitation • The clinical efficacy of postural drainage and chest percussion remains unsubstantiated
CHIRURGICAL INTERVENTIONS/ADDITIONAL PROCEDURES
Lung transplantation for individuals with severe incapacitation: Inpatient considerations
Preliminary Stabilization
• Outpatient management of uncomplicated patients • Administration of low-flow oxygen therapy and bronchodilators in the emergency department for acute exacerbations
• Commencement of suitable antibiotics if necessary
Criteria for Admission
• Presence of high-risk comorbidities (pneumonia, cardiac arrhythmia, etc.) • Insufficient response to outpatient therapy • Significant exacerbation of dyspnea IV Fluids
Proper hydration to facilitate mucus clearing
Nursing • Supervise intravenous fluid administration • Facilitate mucus clearance
Criteria for Discharge
• Symptoms and oxygenation revert to baseline • Hemodynamic equilibrium
• Capacity for ambulation
CONTINUING TREATMENT POST-CARE SUGGESTIONS
• Reassessment of the patient within four weeks to evaluate symptom improvement and necessity for oxygen therapy Routine spirometry should be administered to stable patients with chronic bronchitis and FEV1 <50% of predicted value who experience frequent exacerbations while undergoing inhaled corticosteroid therapy.< />pan>
Patient Surveillance
• Evaluate the patient's capacity to manage environmental requirements • Supervise the administration of bronchodilators
No special diet has been shown beneficial for bronchitis.
Patient Education: Smoking Cessation
• Elimination of contact with environmental irritants • Limitation of strenuous activities in individuals with chronic bronchitis
PROGNOSIS
• Individuals with acute bronchitis typically exhibit a favorable prognosis. • The cessation of smoking has been demonstrated to correlate with a decelerated decline in pulmonary function.
COMPLICATIONS
• Respiratory insufficiency
• Pulmonary emphysema
• Right ventricular failure
• Lack of therapeutic response due to the following factors:
– Disease progression too advanced or therapy excessively delayed – Incorrect diagnosis – Insufficient antibiotic dosage – Compromised or weakened host
- Existence of resistant microorganisms, such as Pseudomonas
BRONCHITIS
Bronchitis is an inflammation of the lining of the tracheobronchial tree. It is typically categorized as acute or chronic.
Acute bronchitis is defined by a cough, sometimes accompanied by sputum production, lasting less than three weeks.
Chronic bronchitis is clinically defined as a chronic productive cough lasting a minimum of 3 months over a span of 2 consecutive years.
Epidemiology
Occurrence
Chronic bronchitis impacts over 9.5 million Americans annually.
Approximately 10 million individuals pursue medical treatment for acute bronchitis annually.
Acute bronchitis: Present in all age demographics. Affects both males and females equally.
• Chronic bronchitis: Predominantly observed in adults over the age of 50. Males are more adversely impacted than females.
RISK FACTORS
• Acute bronchitis: – Tobacco use – Respiratory irritants, such as exposure to chemicals and air pollution
Upper respiratory tract infections, chronic lung diseases, advanced age, and diminished immunity elevate the risk of acute bronchitis upon exposure to respiratory irritants. • Chronic bronchitis: – Tobacco use – Respiratory irritants, such as exposure to chemicals and air pollution
- Recurrent upper respiratory tract infections, allergies – 50 years of age
Genetics
Heritability exerts a moderate impact on the progression of chronic bronchitis.
GENERAL PREVENTION MEASURES
• Refrain from smoking and exposure to second-hand smoke and irritants. • Avoid interaction with those suffering from upper respiratory tract diseases. Annual influenza vaccination; pneumococcal vaccination every 5 to 10 years for individuals aged 65 or older or those with chronic diseases.
PATHOPHYSIOLOGY
• Irritation of bronchial lining tissue causes hyperemia and edema of the mucous membrane • Excessive mucus production • Hyperreactivity of bronchial smooth muscle resulting in bronchospasm • Increased airflow resistance leading to hypoventilation, subsequently causing hypercarbia and hypoxemia
CAUSE
• Acute bronchitis: - often induced by viral pathogens:
Viruses Influenza A and B Parainfluenza virus Respiratory syncytial virus
Coronavirus and Adenovirus Rhinovirus - Atypical microorganisms are significant contributors in certain instances:
Mycoplasma pneumoniae Chlamydia pneumoniae Bordetella pertussis: Chronic bronchitis
– Tobacco use – Environmental contaminants • Acute aggravation of chronic bronchitis: Haemophilus influenzae
– Moraxella catarrhalis – Pseudomonas aeruginosa and Enterobacteriaceae are more frequent in patients with significant lung function impairment
Streptococcus pneumoniae – Viral infections – Chlamydophila pneumoniae
- Environmental variables (atmospheric contaminants, allergens, thermal fluctuations, irritants such as dust and tobacco smoke)
FREQUENTLY CO-OCCURRING CONDITIONS
• Upper respiratory tract infection • Bronchial asthma • Chronic bronchitis linked with emphysema
chronic obstructive pulmonary disease
DIAGNOSTIC HISTORY
• Acute bronchitis:
– Recent history of a respiratory infection or sinusitis – Exposure to allergens or irritants – Occupational history involving exposure to irritants - Primary or secondary smoking
• Chronic bronchitis: – As previously mentioned – History of productive cough • Acute aggravation of chronic bronchitis: – Elevated dyspnea – Augmented sputum output – Enhanced sputum purulence Symptoms may encompass moderate fever, sore throat, exertional dyspnea, wheezing, chest tightness, chest discomfort, weariness, malaise, and headaches.
PHYSICAL EXAMINATION
• Fever is infrequent • Tachypnea and tachycardia are attributable to infection
• Indicators of upper respiratory tract infection • Harsh breath sounds/wheezing/prolonged expiration • Decline in respiratory function typically arises with acute exacerbations of chronic bronchitis
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory
Preliminary laboratory examinations
• Complete Blood Count (CBC) • Sputum cultures to identify particular pathogenic bacteria • Serum procalcitonin may assist in determining whether individuals require antibiotics (2).
• Pulse oximetry and arterial blood gas analyses
Subsequent Actions & Unique Considerations
Spirometry may be conducted many weeks post-recovery to evaluate lung function and measure airway blockage.
Imaging: Preliminary Strategy
Chest radiograph to exclude pneumonia
Subsequent Actions & Unique Considerations
Subsequent chest radiography is typically unnecessary.
Diagnostic Procedures and Additional Methods
• Assessment of pulmonary function • Bronchoscopy Pathological Findings
• Acute bronchitis:
Mucosal or submucosal edema
- Inflammatory cells in the mucosa and submucosa • Chronic bronchitis:
– Hyperplasia of goblet cells – Inflammatory cells in the mucosa and submucosa Mucus obstruction; smooth muscle hyperplasia.
DIFFERENTIAL DIAGNOSIS
• Asthma • Bronchiolitis • Pneumonia • Pharyngitis
• Bronchiectasis • Chronic sinusitis • Pulmonary embolism with infarction • Congestive heart failure
• Wegener's granulomatosis • Sarcoidosis • Atelectasis • Chemical pneumonitis • Gastroesophageal reflux disease
THERAPEUTIC PHARMACEUTICAL
Initial Line
• Acute bronchitis: Treatment is not indicated unless the following conditions are present (3–5):
– Influenza virus:
Oseltamivir 75 mg orally, twice daily for five days Zanamivir, 2 inhalations (5 mg each inhalation) Twice daily for five days
– Bordetella pertussis:
Azithromycin for 5 days, administered at a dosage of 500 mg on the first day and 250 mg on subsequent days. Two to five Erythromycin 500 mg four times daily for 14 days Clarithromycin 500 mg twice day for 7 days
M. pneumoniae/C. pneumoniae:
No treatment (no persuasive evidence indicating enhanced outcomes from the use of antibacterial medicines)
Azithromycin for 5 days, administered at a dosage of 500 mg on the first day and 250 mg on subsequent days. Doxycycline 100 mg twice day for 5 days
• Acute aggravation of chronic bronchitis
Bacterial infections: – Amoxicillin 250–500 mg orally every 8 hours; – Amoxicillin and clavulanate 500 mg orally every 8 hours for 5–10 days; – Trimethoprim–sulfamethoxazole 160 mg trimethoprim/800 mg sulfamethoxazole orally every 12 hours for 5–10 days.
Doxycycline 100 mg orally twice day on day 1, followed by 100 mg orally once daily for 5 to 10 days.
– Short-term administration of quinolones or macrolides (for 5 days) is not less effective than prolonged treatment (7–10 days) (6)[A].
Levofloxacin 250 mg orally twice daily or 500 mg orally once daily for five days.
Ciprofloxacin 250–500 mg orally, twice day for five days. - Clarithromycin 250–500 mg orally twice daily for 5 days
- Azithromycin for 5 days: 500 mg on day 1 and 250 mg on days 2 to 5. Line
• Acute bronchitis: – B. pertussis: Trimethoprim-sulfamethoxazole 1600 mg daily for 14 days or 800 mg twice day for 14 days
SUPPLEMENTARY THERAPY
General Measures • Avoidance of environmental irritants • Administration of bronchodilators for dyspnea management • Implementation of low-flow oxygen therapy during exacerbations • Utilization of systemic corticosteroids during exacerbations • Employment of antitussive agents (codeine and dextromethorphan) for short-term symptomatic relief of cough in patients with acute and chronic bronchitis Referral Considerations
Recurrent and intense exacerbations
Supplementary Treatments
• Pulmonary rehabilitation • The clinical efficacy of postural drainage and chest percussion remains unsubstantiated
CHIRURGICAL INTERVENTIONS/ADDITIONAL PROCEDURES
Lung transplantation for individuals with severe incapacitation: Inpatient considerations
Preliminary Stabilization
• Outpatient management of uncomplicated patients • Administration of low-flow oxygen therapy and bronchodilators in the emergency department for acute exacerbations
• Commencement of suitable antibiotics if necessary
Criteria for Admission
• Presence of high-risk comorbidities (pneumonia, cardiac arrhythmia, etc.) • Insufficient response to outpatient therapy • Significant exacerbation of dyspnea IV Fluids
Proper hydration to facilitate mucus clearing
Nursing • Supervise intravenous fluid administration • Facilitate mucus clearance
Criteria for Discharge
• Symptoms and oxygenation revert to baseline • Hemodynamic equilibrium
• Capacity for ambulation
CONTINUING TREATMENT POST-CARE SUGGESTIONS
• Reassessment of the patient within four weeks to evaluate symptom improvement and necessity for oxygen therapy Routine spirometry should be administered to stable patients with chronic bronchitis and FEV1 <50% of predicted value who experience frequent exacerbations while undergoing inhaled corticosteroid therapy.< />pan>
Patient Surveillance
• Evaluate the patient's capacity to manage environmental requirements • Supervise the administration of bronchodilators
No special diet has been shown beneficial for bronchitis.
Patient Education: Smoking Cessation
• Elimination of contact with environmental irritants • Limitation of strenuous activities in individuals with chronic bronchitis
PROGNOSIS
• Individuals with acute bronchitis typically exhibit a favorable prognosis. • The cessation of smoking has been demonstrated to correlate with a decelerated decline in pulmonary function.
COMPLICATIONS
• Respiratory insufficiency
• Pulmonary emphysema
• Right ventricular failure
• Lack of therapeutic response due to the following factors:
– Disease progression too advanced or therapy excessively delayed – Incorrect diagnosis – Insufficient antibiotic dosage – Compromised or weakened host
- Existence of resistant microorganisms, such as Pseudomonas
0 Comments
